Siponimod pharmacokinetics, safety and tolerability in combination with the CYP2C9/3A4 inducer, rifampin in healthy subjects

被引：0
|
作者：
Gardin, A. [1 ]
Gray, C. [2 ]
Neelakantham, S. [3 ]
Huth, F. [1 ]
Davidson, A. M. [4 ]
Dumitras, S. [1 ]
Legangneux, E. [1 ]
Shakeri-Nejad, K. [1 ]
机构：
[1] Novartis Inst Biomed Res, Basel, Switzerland
[2] Novartis Pharmaceut, E Hanover, NJ USA
[3] Novartis Healthcare Private Ltd, Hyderabad, Andhra Pradesh, India
[4] PPD, Austin, TX USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2017年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P796
引用
收藏
页码：409 / 409
页数：1
相关论文
共 50 条
  • [31] Pharmacokinetics of CYP2C9, CYP2C19, and CYP2D6 substrates in healthy Chinese and European subjects
    Sijie Lu
    R. A. Nand
    J. S. Yang
    Gang Chen
    A. S. Gross
    European Journal of Clinical Pharmacology, 2018, 74 : 285 - 296
  • [32] Effects of CYP2C9*1/*3 genotype on the pharmacokinetics of flurbiprofen in Korean subjects
    Lee, Yun-Jeong
    Byeon, Ji-Yeong
    Kim, Young-Hoon
    Kim, Se-Hyung
    Choi, Chang-Ik
    Bae, Jung-Woo
    Sohn, Uy-Dong
    Jang, Choon-Gon
    Lee, Jeongmi
    Lee, Seok-Yong
    ARCHIVES OF PHARMACAL RESEARCH, 2015, 38 (06) : 1232 - 1237
  • [33] Effects of CYP2C9*1/*3 genotype on the pharmacokinetics of flurbiprofen in Korean subjects
    Yun-Jeong Lee
    Ji-Yeong Byeon
    Young-Hoon Kim
    Se-Hyung Kim
    Chang-Ik Choi
    Jung-Woo Bae
    Uy-Dong Sohn
    Choon-Gon Jang
    Jeongmi Lee
    Seok-Yong Lee
    Archives of Pharmacal Research, 2015, 38 : 1232 - 1237
  • [34] Effects of CYP2C9 and CYP2C19 polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide in healthy Korean subjects.
    Choi, C.
    Bae, J.
    Kim, M.
    Jang, C.
    Lee, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 : S68 - S68
  • [35] Siponimod and CYP2C9 Allele Prevalence Among Blacks
    Liu, Michelle
    Obeng, Aniwaa Owusu
    JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 60 (04): : 429 - 431
  • [36] Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes
    Niemi, M
    Cascorbi, I
    Timm, R
    Kroemer, HK
    Neuvonen, PJ
    Kivistö, KT
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 72 (03) : 326 - 332
  • [37] CYP2C9*3and*13 alleles significantly affected the pharmacokinetics of glipizide in healthy Korean subjects.
    Song, Y.
    Kim, N.
    Bae, J.
    Kim, M.
    Jang, C.
    Lee, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 : S68 - S69
  • [38] The pharmacokinetics of S-warfarin in healthy subjects carrying different CYP2C9 genotypes.
    Shaoul, H.
    Blotnick, S.
    Muszkat, M.
    Caraco, Y.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 : S19 - S19
  • [39] Safety of voriconazole in a patient with CYP2C9*2/CYP2C9*2 genotype
    Geist, Marcus J. P.
    Egerer, Gerlinde
    Burhenne, Juergen
    Mikus, Gerd
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (09) : 3227 - 3228
  • [40] Effect of rifampin (a potent inducer of CYP450 3A4) on the pharmacokinetics of Gleevec™ (Glivec®, STI571, imatinib)
    Bolton, AE
    Peng, B
    Hubert, M
    Seiberling, M
    Keller, U
    Krebs-Brown, A
    Capdeville, R
    Hensley, ML
    BLOOD, 2002, 100 (11) : 214B - 214B
12345